Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)Completed
NCT04180488Phase 3Updated Aug 20, 2025
Sponsor: Sanofi
Chronic Spontaneous Urticaria
United States, Argentina, Canada, China, France +6 more
Best Practice Study of Diabetes Type 2 Management in Primary Care in SwitzerlandCompleted
NCT04216875N/AUpdated Aug 20, 2025
Sponsor: QualiCCare
Diabetes Mellitus, Type 2 · Primary Care
Switzerland
A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech RepublicCompleted
NCT05527964N/AUpdated Aug 15, 2025
Sponsor: Sanofi
Atopic Dermatitis
Czechia
Description of Patients With Type 1 Diabetes Treated With TeplizumabCompleted
NCT06892002N/AUpdated Aug 15, 2025
Sponsor: Sanofi
Type 1 Diabetes
United States, Israel
Observational Evaluation of Atopic Dermatitis in Pediatric PatientsActive Not Recruiting
NCT03687359N/AUpdated Aug 15, 2025
Sponsor: Sanofi
Dermatitis Atopic
United States, Argentina, Australia, Brazil, Canada +15 more
Baby Detect : Genomic Newborn ScreeningCompleted
NCT05687474N/AUpdated Aug 12, 2025
Sponsor: Centre Hospitalier Universitaire de Liege
Congenital Adrenal Hyperplasia · Familial Hyperinsulinemic Hypoglycemia 1 · Phosphoglucomutase 1 Deficiency · Maturity Onset Diabetes of the Young
Belgium
Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD EmphysemaCompleted
NCT05856331Phase 2Updated Aug 11, 2025
Sponsor: Sanofi
Alpha 1-Antitrypsin Deficiency · Emphysema
United States, Australia, Denmark, New Zealand, Poland +3 more
Surveillance of Suspected Dengue Cases for Access to Care for Subjects Identified as Seronegative or Undetermined Before Receiving CYD Dengue Vaccine in Previous Clinical Studies in ColombiaActive Not Recruiting
NCT04113330N/AUpdated Aug 8, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue Fever
Colombia
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid TumorsTerminated
NCT04717375Phase 1, Phase 2Updated Aug 7, 2025
Sponsor: Sanofi
Cancer · Neoplasm
United States, Canada, Israel, United Kingdom
Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid TumorsCompleted
NCT03324113Phase 1Updated Aug 5, 2025
Sponsor: Sanofi
Neoplasm Malignant
Japan
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)Recruiting
NCT03936335N/AUpdated Aug 3, 2025
Sponsor: Regeneron Pharmaceuticals
Adverse Pregnancy Outcomes · Atopic Dermatitis
United States
Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering MyelomaRecruiting
NCT06762769Phase 2Updated Aug 1, 2025
Sponsor: University College, London
Smouldering Myeloma
United Kingdom
CRICKET Study, Coronary Calcium Scores in Patients With Chronic Kidney DiseaseWithdrawn
NCT00142636N/AUpdated Aug 1, 2025
Sponsor: United States Naval Medical Center, San Diego
Chronic Kidney Disease
United States
A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of RelapseActive Not Recruiting
NCT01952223Phase 3Updated Jul 30, 2025
Sponsor: UNICANCER
Adenocarcinoma of Prostate · Progression of Prostate Cancer
France
Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of AgeCompleted
NCT04144179Phase 1Updated Jul 29, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza
United States
A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving DupilumabActive Not Recruiting
NCT06169527N/AUpdated Jul 14, 2025
Sponsor: Sanofi
Atopic Dermatitis
France
A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid ArthritisCompleted
NCT06073093Phase 2Updated Jul 11, 2025
Sponsor: Sanofi
Rheumatoid Arthritis
United States, Argentina, Brazil, Canada, Chile +14 more
Isa-RVD Study in Patients With Newly Diagnosed Multiple MyelomaActive Not Recruiting
NCT05123131Phase 2Updated Jul 8, 2025
Sponsor: Cancer Trials Ireland
Multiple Myeloma
Denmark, Ireland
Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)Terminated
NCT03816839Phase 1Updated Jul 7, 2025
Sponsor: Sanofi
Breast Cancer
Japan
Dupilumab in the Treatment of KeloidsCompleted
NCT04988022Phase 4Updated Jul 4, 2025
Sponsor: Icahn School of Medicine at Mount Sinai
Keloid
United States
Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as ToddlersActive Not Recruiting
NCT04936685Phase 3Updated Jul 4, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation · Healthy Volunteers
Finland, Germany, Hungary, Spain
Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD StudyCompleted
NCT05131477Phase 2Updated Jul 3, 2025
Sponsor: Kymab Limited
Eczema · Atopic Dermatitis
United States, Australia, Bulgaria, Canada, Czechia +7 more
Compassionate Use of Dupilumab for Adult Patients With Bullous PemphigoidApproved For Marketing
NCT05906706N/AUpdated Jul 3, 2025
Sponsor: Regeneron Pharmaceuticals
Bullous Pemphigoid
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)Completed
NCT04410978Phase 3Updated Jul 2, 2025
Sponsor: Sanofi
Relapsing Multiple Sclerosis
United States, Austria, Belarus, Bulgaria, Canada +19 more
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)Completed
NCT04411641Phase 3Updated Jul 2, 2025
Sponsor: Sanofi
Non-relapsing Secondary Progressive Multiple Sclerosis
United States, Argentina, Australia, Austria, Belarus +26 more

Previous page Next page